Perspective Therapeutics (NYSE: CATX) outlines 212Pb cancer pipeline update

(Moderate)

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Perspective Therapeutics, Inc. filed a current report to note that it updated its corporate presentation on June 1, 2026 and furnished it as Exhibit 99.1. The presentation highlights a strategy focused on next-generation radiopharmaceuticals using the 212Pb isotope to treat solid tumors through a theranostic approach and integrated isotope production.

The deck describes regional daily production and direct-to-hospital delivery, along with a wholly owned 212Pb-based oncology portfolio. Key programs include VMT-α-NET for SSTR2+ neuroendocrine tumors, VMT01 for melanoma, and PSV359 targeting FAP-ɑ in solid tumors, all in ongoing Phase 1/2a or early clinical trials, with references to safety, exposure, and preliminary anti-tumor activity.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Filing date: June 1, 2026 Isotope: 212Pb VMT-α-NET patients: 68 patients +2 more

5 metrics

Filing date June 1, 2026 Date of updated corporate presentation and 8-K report

Isotope 212Pb Core isotope used in next-generation radiopharmaceutical programs

VMT-α-NET patients 68 patients Blood creatinine follow-up for all patients treated in VMT-α-NET data

VMT01 dose level 3.0 mCi Dose where preliminary anti-tumor activity was observed for VMT01 in melanoma

Trial stage Phase 1/2a Ongoing trials for VMT-α-NET, VMT01, and PSV359

Key Terms

radiopharmaceuticals, theranostic, SSTR2+ neuroendocrine tumors, checkpoint inhibitors, +2 more

6 terms

radiopharmaceuticals medical

"Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals"

Radiopharmaceuticals are medicines that carry tiny amounts of radioactive material to help doctors see or treat disease inside the body, acting like a tracer dye for imaging or a microscopic guided missile for targeted therapy. They matter to investors because their safety, regulatory approval, production complexity, short shelf life and hospital reimbursement determine how quickly they can reach patients and generate revenue, affecting a company’s sales potential and risk profile.

theranostic medical

"Advancing a Theranostic Approach"

A theranostic is a single medical approach or agent that combines diagnosis and treatment—using a test or imaging step to find patients likely to benefit, then delivering a targeted therapy tied to that same marker. For investors, theranostics can speed development, lower the chance of failed trials and concentrate sales on the right patients, like a smart key that both locates the correct lock and opens it, potentially improving clinical and commercial success.

SSTR2+ neuroendocrine tumors medical

"SSTR2+ Neuroendocrine Tumors is a Large, Growing Market"

checkpoint inhibitors medical

"Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind"

Checkpoint inhibitors are drugs that help the immune system recognize and attack cancer cells by blocking certain proteins that normally keep immune responses in check. They act like brakes being released on the immune system, allowing it to target tumors more effectively. These medicines are important for investors because they represent a promising area of cancer treatment with growing research, development, and commercial potential.

MC1R medical

"VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma"

MC1R is a human gene that encodes a protein on cell surfaces involved in skin and hair pigmentation and in cellular responses to ultraviolet light. For investors, changes or mutations in MC1R matter because they can influence disease risk (notably certain skin cancers), be used as biomarkers, or serve as targets for diagnostics and therapies—think of it as a control switch that drug developers or diagnostic companies might aim to measure or modify.

FAP-ɑ medical

"FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 06/01/2026 - 06:31 AM Accepted by SEC EDGAR 06/01/2026 - 06:30 AM

FAQ

What did Perspective Therapeutics (CATX) disclose in this 8-K filing?

Perspective Therapeutics reported it updated its corporate presentation and filed it as Exhibit 99.1. The presentation outlines its focus on next-generation 212Pb radiopharmaceuticals, solid tumor indications, clinical programs, and integrated isotope production and delivery across regional manufacturing sites.

Which cancer programs does Perspective Therapeutics (CATX) highlight in its new presentation?

The presentation highlights three main 212Pb-based programs: VMT-α-NET for SSTR2+ neuroendocrine tumors, VMT01 for melanoma targeting MC1R, and PSV359 targeting FAP-ɑ in advanced solid tumors, each described in the context of ongoing Phase 1/2a or early clinical trials.

How is Perspective Therapeutics (CATX) positioning its 212Pb radiopharmaceutical platform?

Perspective Therapeutics emphasizes next-generation 212Pb radiopharmaceuticals engineered for targeted oncology, using a theranostic approach. The presentation stresses structural chemistry optimization, careful isotope selection, and a diverse, wholly owned 212Pb-based portfolio aimed at expanding treatment options across multiple solid tumor indications.

What clinical data references appear in Perspective Therapeutics’ updated deck?

The deck references ongoing Phase 1/2a trials, including VMT-α-NET data with follow-up for 68 treated patients and ASCO 2026 analyses. It also notes preliminary anti-tumor activity at a 3.0 mCi VMT01 dose in melanoma and describes safety and disease control observations across doses.

How does Perspective Therapeutics (CATX) plan to deliver its radiopharmaceutical products?

The presentation describes a direct-to-hospital delivery model supported by integrated isotope production. It highlights daily production at regional manufacturing sites to ensure a supply of ready-to-administer 212Pb-based radiopharmaceutical products, aiming to reach a large addressable solid tumor market.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): June 01, 2026

    

Perspective Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-33407	41-1458152
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

c/o Perspective Therapeutics, Inc. 2401 Elliott Avenue Suite 320
Seattle, Washington		98121
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: (206) 676-0900

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	CATX	NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On June 1, 2026, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.		Description
99.1		Corporate Presentation.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			PERSPECTIVE THERAPEUTICS, INC.

Date:	June 1, 2026	By:	/s/ Joel Sendek
			Joel Sendek Chief Financial Officer

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

Engineering the Alpha Advantage in Targeted Oncology

Unlocking New Treatment Options Across Solid Tumors:

Optimizing the Entire System

Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals

Optimizing Structural Chemistry:

Choosing The Right Isotope

Not All ²¹²Pb Programs Are Created Equal

Advancing a Theranostic Approach:

Solid Tumors are an Attractive Market for Radiopharmaceuticals

Expanding the Addressable Market

Direct-to-Hospital Delivery through Integrated Isotope Production

Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product

Reaching the Largest Addressable Market with Regional Manufacturing

Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio

SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need

VMT-⍺-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2

Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT-⍺-NET in NETs

VMT-⍺-NET: Baseline Patient Characteristics in ASCO 2026 Data Analysis

Patient Exposure and Follow-up with [212Pb]VMT-α-NET in ASCO 2026 Data Analysis

VMT-α-NET Responses Deepen Over Time

VMT-⍺-NET: Durable Disease Control Across All Doses

Spider Plot of Tumor Change Over Time by Patient

Best-in-class Safety Profile1

Blood Creatinine During Follow-up for All Patients Treated (n=68)

VMT-α-NET’s Compelling Profile Supports Potential Registration Study at Current Dose Level

Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind

VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma

Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma

Preliminary Anti-tumor Activity Observed at 3.0 mCi Dose of VMT01

Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 10% of Patients)

VMT01 is Well-tolerated with Initial Anti-tumor Activity Supporting Further Development

FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential

PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors

Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors

PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent

Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain

A Decade of Deliberate, End-to-End Engineering

Built Over a Decade:

Abbreviations

APPENDIX

NETs Trials

Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment

Refractory Metastatic Melanoma Trials

ICI Combo Rationale: Strong Synergy with [212Pb]VMT01 in Melanoma

Construct designed for better clinical outcome

212Pb Uniquely Suited for Combination with Immune Check Point Inhibitors

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

2 documents

Press Releases

EX-99.1 EX-99.1 19.2 KB